Day: September 2, 2021

Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces an abstract describing a drug-drug interaction study assessing the effect of CYP2C9 inhibitor, fluconazole, on the pharmacokinetics of nebulized ensifentrine in healthy individuals has been published by the European Respiratory Society (“ERS”) International Congress 2021. The abstract is available on the ERS website and will appear in a supplement of the peer reviewed journal, European Respiratory Journal. Ensifentrine is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3” and...

AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial MARSEILLE, France, Sept. 02, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that two oral presentations will be highlighted at the ESMO 2021 Virtual Congress. AstraZeneca will present a late-breaker abstract on the COAST Phase 2 trial, highlighting progression-free survival (PFS) results for novel durvalumab combinations with potential new medicines, including Innate’s monalizumab, and oleclumab, an anti-CD73 monoclonal antibody, in unresectable, Stage III non-small cell lung cancer (NSCLC).   Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed...

Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio DURHAM, N.C. and NEW YORK and LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a clinical stage biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an exclusive license agreement to explore Tiziana’s foralumab, a fully human anti-CD3 monoclonal antibody (mAb), as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clinical outcome of CAR T cell therapy. The...

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference and participate in a fireside chat with Oppenheimer Senior Biotech Analyst Justin Kim at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Details are as follows: Event: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: Monday, September 13thTime: 7:00am Eastern US Daylight Time Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date: Wednesday, September 22ndTime: 10:45am Eastern US...

VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) — Silver Bull Resources, Inc. (OTCQB: SVBL, TSX: SVB) (“Silver Bull” or the “Company”) is pleased to announce the timing and additional details regarding the previously announced distribution (the “Distribution”) to Silver Bull shareholders of shares of Arras Minerals Corp. (“Arras”). Pursuant to the Distribution, shareholders of Silver Bull common stock as of September 10, 2021 (the “Record Date”) will be entitled to receive one common share of Arras for each share of Silver Bull common stock held as of that date. The Distribution is scheduled to occur on September 24, 2021 (the “Distribution Date”). Immediately following completion of the Distribution, Silver Bull’s shareholders will be issued shares in Arras so that, collectively, they will own approximately 84% of...

GUANGZHOU, China, Sept. 01, 2021 (GLOBE NEWSWIRE) — Fanhua Inc. (“Fanhua” or “the Company”) (Nasdaq: FANH), a leading independent financial services provider in China, today announced that the record date for its upcoming quarterly cash dividend for the second quarter of 2021 will be changed from the previously announced September 7, 2021 to September 13, 2021. The dividend amount of US$0.15 per ADS, or US$0.0075 per ordinary share, which is payable on or around September 23, 2021, remains unchanged. The dividends to be paid to the ADS holders through the depositary bank will be subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. About Fanhua Inc. Fanhua Inc. is a leading independent financial services provider. Through our online platforms and offline sales and service network, we...

SYDNEY, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) — Arowana’s private credit investment arm has reached an agreement with ICAM Duxton STC Holdings Pty Ltd (“ICAM” or “the Borrower”) regarding the early settlement of its secured infrastructure debt facility for the Lucky Bay Port in South Australia. This has enabled co-investors with Arowana to realise a return in excess of the target IRR of 15%. Lucky Bay provides an alternative grain supply channel for grain growers and other commodity suppliers on the Eyre Peninsula in South Australia. It is run by ICAM Duxton Port Infrastructure Trust (IDPIT) with ICAM as the fund manager and T-Ports as the operator, specialising in innovative logistical solutions for the export of Australian commodities. T-Ports was established by IDPIT in 2018 to initiate construction and project management...